FindTrial
Sign In

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma or Ocular Hypertension

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-028-02
Enrollment
Unknown
Registered
2002-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

GROUP II Type of group
travoprost 0.004% once a day (night) for twelve weeks. Group name:GROUP II Type of group
Latanoprost 0.005% once a day (night) for six weeks. then Travoprost 0.004% once a day (night) for six weeks.

Sponsors

ALCON RESEARCH LTD.,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients of any race and either sex with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension.

Exclusion criteria

Exclusion criteria: Better corrected visual acuity worse than 0.6 logMar in one eye or the other. History of severe eye disease, chronic or recurrent. History of ocular traumatism during the last six months. History of ocular infection or eye inflammation during the last three months.

Design outcomes

Primary

MeasureTime frame
Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated—

Secondary

MeasureTime frame
Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated—

Countries

Peru, United States

Outcome results

None listed

Source: REPEC (via WHO ICTRP)